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Abstract
Background: Hypertension affects 29% of the adult U.S. population and is a leading cause of heart
disease, stroke, and kidney failure. Despite numerous effective treatments, only 53% of people with
hypertension are at goal blood pressure. The chronic care model suggests that blood pressure
control can be achieved by improving how patients and physicians address patient self-care.
Methods and design: This paper describes the protocol of a nested 2 × 2 randomized controlled
trial to test the separate and combined effects on systolic blood pressure of a behavioral
intervention for patients and a quality improvement-type intervention for physicians. Primary care
practices were randomly assigned to the physician intervention or to the physician control
condition. Physician randomization occurred at the clinic level. The physician intervention included
training and performance monitoring. The training comprised 2 internet-based modules detailing
both the JNC-7 hypertension guidelines and lifestyle modifications for hypertension. Performance
data were collected for 18 months, and feedback was provided to physicians every 3 months.
Patient participants in both intervention and control clinics were individually randomized to the
patient intervention or to usual care. The patient intervention consisted of a 6-month behavioral
intervention conducted by trained interventionists in 20 group sessions, followed by 12 monthly
phone contacts by community health advisors. Follow-up measurements were performed at 6 and
18 months. The primary outcome was the mean change in systolic blood pressure at 6 months.
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Secondary outcomes were diastolic blood pressure and the proportion of patients with adequate
blood pressure control at 6 and 18 months.
Discussion: Overall, 8 practices (4 per treatment group), 32 physicians (4 per practice; 16 per
treatment group), and 574 patients (289 control and 285 intervention) were enrolled. Baseline
characteristics of patients and providers and the challenges faced during study implementation are
presented. The HIP interventions may improve blood pressure control and lower cardiovascular
disease risk in a primary care practice setting by addressing key components of the chronic care
model. The study design allows an assessment of the effectiveness and cost of physician and patient
interventions separately, so that health care organizations can make informed decisions about
implementation of 1 or both interventions in the context of local resources.
Trial registration: ClinicalTrials.gov identifier NCT00201136
Background
Approximately 50 million adult Americans have hyper-
tension [1], which is the most prevalent risk factor for car-
diovascular and kidney disease [2] and accounts for
approximately 35% of atherosclerotic cardiovascular dis-
ease (CVD) [3]. Fortunately, the treatment of hyperten-
sion reduces associated risks: lowering blood pressure
(BP) by a variety of strategies reduces the risk of stroke by
approximately 35%, congestive heart failure by 42%, and
coronary heart disease by 28% [4-7]. Therefore, an impor-
tant key to reducing the burden of hypertension-related
CVD is to increase the proportion of patients who achieve
optimal BP control. To promote this goal, the Joint
National Committee on Prevention, Evaluation, Detec-
tion, and Treatment of High Blood Pressure (JNC) has
established guidelines that have been widely dissemi-
nated to practitioners through the National Institutes of
Health High Blood Pressure Education Program and other
organizations [8].
The latest JNC guidelines (JNC-7), published in 2003,
classify BP into stages and provide recommendations for
treatment and follow-up. The recommended goal for
patients with uncomplicated hypertension is an average
systolic BP of less than 140 mm Hg and a diastolic BP of
less than 90 mm Hg. For patients with certain comorbid
conditions that increase risk (i.e., diabetes mellitus and
chronic kidney disease), the goal BP is less than 130/80
mm Hg [8].
Treatments for high blood pressure are classified as life-
style modification or medication. The guidelines direct
physicians to prescribe lifestyle modification to all
patients with BP that is above the optimal category (>
120/80 mm Hg). The recommendations for lifestyle mod-
ification are evidence-based and include adoption of a
healthy dietary pattern such as the Dietary Approaches to
Stop Hypertension (DASH) diet [9], losing weight if over-
weight, reducing sodium intake, increasing physical activ-
ity, and limiting alcohol intake [8]. Each of these
behavioral interventions has been shown to lower BP and
contribute to hypertension control. For medication ther-
apy, the guidelines indicate when and whom to treat and
also provide advice on choice of drug, when and how to
adjust doses, and how to minimize non-adherence to
therapy. The explicit intent of the guidelines is to assist
physicians in achieving goal BP in the majority of their
patients.
Two behaviors that could improve BP control are physi-
cians' adherence to JNC-7 guidelines and patients' adher-
ence to lifestyle recommendations and medication
regimens. Several similarities exist between behavioral
models that attempt to explain why physicians do or do
not follow guidelines for preventive care [10,11] and
those that attempt to explain why patients do or do not
adopt healthy lifestyle behaviors [12,13]. For the physi-
cian, awareness (knowledge), motivation, and confidence
(self-efficacy) all influence adherence to guidelines. For
instance, physicians who do not know about or do not
feel motivated to follow the JNC guidelines are not likely
to prescribe them, nor are physicians who have the knowl-
edge and motivation but lack confidence to follow the
guidelines. Non-behavioral factors can also influence
physicians' actions. These include external or systems-
level factors such as time constraints, resources, and sys-
tems to prompt or remind physicians of the guidelines
[10,11,14].
Similarly, behavioral factors may also influence patients'
adherence to lifestyle recommendations and medications
[12,13]. Patients who are unaware that they need to
change their behavior or who are not motivated will not
change. In addition, external factors including food avail-
ability and environmental structures may affect how
patients adhere to a healthy lifestyle. The Hypertension
Improvement Project (HIP) behavioral interventions were
designed to target the same psychosocial mediators and
systems factors for both physicians and patients, pre-
sented graphically in Figure 1.Trials 2009, 10:13 http://www.trialsjournal.com/content/10/1/13
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Strategies for implementing recommended practice to
improve clinical outcomes include dissemination of
printed educational materials (e.g., clinical practice guide-
lines), physician and patient training, feedback to physi-
cians, dissemination of information linked to
performance (e.g., audit and feedback, reminder systems),
clinical performance measures (CPMs), and simple clini-
cal bedside tools. Although randomized trials of these
strategies are rare, there is evidence that such tools can
change medical provider behavior and improve clinical
outcomes [15-17]. A major challenge is the integration of
practice improvement strategies into the flow of clinical
care; to accomplish this, health researchers and providers
have borrowed techniques of Continuous Quality
Improvement (CQI). It is the application of a CQI
approach–applying tools shown to be effective–that
forms the foundation for the HIP physician intervention.
The patient also plays a critical role in hypertension care.
As noted above, the JNC guidelines include lifestyle mod-
ification for all patients with hypertension. Programs that
result in successful lifestyle behavior change are generally
based on Social Cognitive Theory [12] and techniques of
behavioral self-management [18]. They are typically con-
structed using the Transtheoretical Model [13,19] and
motivational enhancement approaches [20,21]. These
approaches emphasize the importance of the individual's
ability to regulate behavior by setting goals, developing
specific behavior change plans, monitoring progress
towards the goals, and attaining skills necessary to reach
the goals. Self-efficacy (i.e., one's confidence in perform-
ing a given behavior) and outcome expectations (i.e.,
one's belief that changing behavior leads to a favorable
outcome) are critical mediators of behavior change
[12,22]. An example of this approach can be found in the
PREMIER trial of lifestyle interventions for blood pressure
control–a multi-center trial sponsored by the National
Heart, Lung, and Blood Institute that tested the effects on
BP of 2 multi-component lifestyle interventions, relative
to an advice-only control condition [23]. The PREMIER
study demonstrated that a 6-month intensive behavioral
intervention leads to healthy lifestyle changes, significant
reductions in BP, and improved control of hypertension.
As is true for most chronic illnesses, hypertension man-
agement requires extensive efforts from physicians and
Psychosocial mediators and systems factors that influence physician and patient adherence to JNC-7 guidelines Figure 1
Psychosocial mediators and systems factors that influence physician and patient adherence to JNC-7 guide-
lines. MD = physician.Trials 2009, 10:13 http://www.trialsjournal.com/content/10/1/13
Page 4 of 14
(page number not for citation purposes)
patients alike, with support from the health care system. It
was hypothesized that a quality improvement approach
would maximize physician adherence to treatment guide-
lines, and a behavioral intervention would improve
patient adherence to lifestyle recommendations. Both
approaches may lead to significant improvements in BP
control with consequent reductions in CVD risk. The HIP
study offers a unique and innovative opportunity to test
this hypothesis by determining, in a randomized control-
led trial, the separate and combined effect on BP of a phy-
sician intervention and a patient intervention. The study
design provides for an assessment of the effectiveness and
cost of implementing the physician and patient interven-
tions separately, thereby allowing health care organiza-
tions to make informed decisions about implementation
of 1 or both interventions in the context of local resources.
As participant enrollment concludes and data cleaning
and analysis begin, this paper describes the protocol of the
HIP trial and discusses the lessons learned thus far from
designing and implementing the study, including issues
encountered and subsequent changes to the study design.
Methods and design
Overview
The HIP study was a nested 2 × 2 randomized controlled
trial of a physician intervention, a patient intervention,
and both combined (Figure 2). All study procedures were
approved by the Duke Institutional Review Board.
Recruitment was conducted in waves: i.e., 2 practices were
initiated every 6 months to allow adequate time for study
personnel to train providers and recruit participants. Each
group of practices was considered a cohort (e.g., the first 2
practices recruited are considered Cohort 1). Nesting
occurred at the level of the practice and the level of the
physician. Primary care practices were randomly assigned
to the physician (MD) intervention or to the MD control
condition. All participating MDs within a given practice
had the same randomization assignment. The MD inter-
vention consisted of training and performance monitor-
ing. Performance data were collected for 18 months, and
feedback was provided to physicians every 3 months
within that timeframe.
Within the practices, patient participants were individu-
ally randomized to the patient intervention or to usual
care. The patient intervention occurred shortly after initi-
ation of the physician intervention and consisted of a 6-
month group-based behavioral intervention conducted
by trained interventionists, followed by brief monthly
phone counseling for 12 months from a community
health advisor (CHA). Follow-up measurements were per-
formed at 6 and 18 months following randomization.
Enrollment and randomization of MDs
To avoid contamination among physicians in the same
practice, randomization occurred at the level of the prac-
tice. Four matched pairs of primary care practices were
randomly assigned to physician intervention or control.
Practices were matched according to specialty (internal
medicine or family practice) and participant mix (percent
of participants with Medicaid or Medicare without supple-
mental insurance). Within each practice, all physicians
were invited to participate, with a goal of enrolling 4 phy-
sicians at each clinic. All physicians at a given clinic were
assigned to the same intervention.
Enrollment and randomization of patients
After enrolling clinics and physicians, participants were
then recruited from the patients of the enrolled physi-
cians. Ten to 15 patients cared for by each participating
MD were enrolled and randomized to the behavioral
intervention or usual care.
Billing codes were used to identify hypertensive patients.
Each participating physician reviewed the list and
removed names of patients considered unsuitable candi-
dates for study participation. Recruitment letters were
mailed on practice letterhead with the physician's name
on the signature line. Patients were asked to call the
research coordinator within 10 working days to decline
participation in the study. After the 10 days, a member
from the study staff called unresponsive patients to assess
their willingness and eligibility to participate (Table 1).
At the first screening visit, the consent form was reviewed
and signed, height, weight and BP were measured, and
body mass index (BMI) was calculated. A self-adminis-
tered medical history questionnaire was used to establish
the final set of eligibility criteria. At a second screening
visit, questionnaires and interviews established the
patient's commitment and ability to participate, and a
fasting blood specimen, 24-hour urine collection, and a
second BP measurement were obtained. Participant base-
line characteristics are shown in Table 2.
Design of the HIP study Figure 2
Design of the HIP study. MD = physician.
Randomize 8 primary care practices
4 Control practices 4 Intervention practices
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After eligibility was established, randomization occurred
using a computer-generated algorithm, stratified by
cohort and by clinic. Participants were randomized in var-
ying block sizes to ensure comparable numbers of partic-
ipants in each assignment over time. Each participant
learned of his/her treatment assignment from a HIP staff
member who was not involved in collecting study meas-
urements. Intervention staff members then instructed par-
ticipants on the details of their assigned intervention.
Content and conduct of physician intervention
The MD control constituted a "usual care" condition. That
is, there was no attempt to change or monitor whatever
procedures were already in place in that practice for qual-
ity improvement and physician education with regard to
BP control. No performance data were collected from
these physicians, and no performance feedback was given.
The active MD intervention consisted of 3 main elements.
The first element included 2 training modules provided as
on-line continuing medical education (CME) courses. The
first module addressed the JNC-7 guidelines and the sec-
ond addressed lifestyle modification for BP control. The
modules were available in 3 formats (streaming audio,
PowerPoint slide show, and print version) so that each
physician could choose the most convenient modality.
Each module required approximately 45 minutes to com-
plete, included a quiz that gave immediate feedback on
the answers, and resulted in CME credit through the Duke
CME office. All physicians completed the modules before
the first group session of the patient intervention.
The second element was an evaluation and treatment
algorithm that summarized the major guidelines set forth
in JNC-7. The BP management algorithm–derived from
the JNC-7 guidelines and formatted as a decision tree–was
mass-produced in a color-coded, laminated pocket card
(Additional file 1) and provided to each physician rand-
omized to the active MD intervention. The algorithm
directly informed the portion of the CPM data form that
was completed by the MD (Additional file 2).
The third element was a CQI-type procedure involving
assessment of CPMs and quarterly feedback to physicians
on their adherence to guidelines, including those related
to lifestyle counseling. At each clinic randomized to the
MD intervention, the clinic staff and participating physi-
cian completed a single-page CPM data form every time
an HIP participant (in either patient treatment group) had
a clinic visit. A clinic nurse completed the top half of the
form (BP at current and last clinic visit, comorbidities),
and the MD completed the bottom half (current BP med-
ications, actions taken during the visit, follow-up inter-
val). In addition, data from non-study participants were
collected on anonymous forms 1 day each month to
increase sample sizes for feedback reports. In both cases,
the form was attached to the billing encounter form to
prompt MDs to complete it. These data were converted
into quarterly feedback reports that indicated to each phy-
sician: 1) the proportion of hypertensive participants with
adequately controlled BP for that quarter and the previous
quarters; 2) the proportion not at goal who had medica-
tion adjustments at the visit; 3) the proportion that
received lifestyle modification counseling; 4) the propor-
tion without diabetes (DM) or chronic kidney disease
(CKD) who were at goal BP and also the proportion pre-
scribed a thiazide diuretic; 5) the proportion with DM
and/or CKD who were at goal BP and also the proportion
prescribed an angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker; and 6) comparisons with
peer MDs for each category.
Content and conduct of the patient intervention
Patient control
Participants randomized to the control group had an indi-
vidual brief visit with an interventionist after randomiza-
tion, during which they received advice and brochures on
lifestyle modification for BP control consistent with JNC-
Table 1: HIP eligibility criteria
Inclusion criteria ￿ Receiving primary care from a randomized physician
￿ Diagnosis of hypertension: Average SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg on at least 2 clinic visits in the past 12 
months or taking antihypertensive medication
￿ Age 25 years or older at the time of the initial screening visit
￿ Willing and able to participate fully in all aspects of the intervention
Exclusion criteria ￿ Cardiovascular event within the past 6 months (if more remote history, eligible with MD approval)
￿ Chronic kidney disease (estimated GFR < 60 ml/min)
￿ Planning to leave the area prior to the anticipated end of participation
￿ Pregnant, breast feeding, or planning pregnancy prior to the end of participation
￿ Current participation in another clinical trial
￿ Investigator discretion for safety or adherence reasons
￿ Household member of another HIP participant or of an HIP staff member
DBP = diastolic blood pressure; GFR = glomerular filtration rate; HIP = Hypertension Improvement Project; MD = physician; SBP = systolic blood 
pressure.Trials 2009, 10:13 http://www.trialsjournal.com/content/10/1/13
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7. At the end of the study (18 months), after the final data
collection visit, participants in the control group were
offered an abbreviated version of the active intervention,
which consisted of 6 weekly group sessions to help them
make lifestyle changes to control BP (wait-list control).
Active intervention: structure and content
The active patient intervention was based on key theoret-
ical constructs developed to guide health behavior change
efforts, and on practical applications from previous trials
of lifestyle change and CVD risk reduction [24-26].
The patient intervention was conducted by 2 intervention-
ists who served in this role in previous studies. Training
for the interventionists was provided by behavioral scien-
tists and nutritionists, and included training in interven-
tion content, group facilitation, and motivational
interviewing [20]. Ongoing quality assurance for interven-
tion delivery was provided through retraining, observa-
tion, and feedback for the interventionists. The patient
intervention consisted of 20 weekly sessions provided
over approximately 6 months, during which the partici-
pants met in small groups (n = 10–15 per group) with an
interventionist. All intervention sessions took place at or
near the participants' clinic site, providing a familiar loca-
tion for these sessions.
Specific behavior change strategies comprising the HIP
patient intervention are listed in Table 3. The materials
developed to deliver the patient intervention included a
leader's guide and a participant manual featuring self-
monitoring tools. The leader's guide provided a standard-
ized framework and structure for each group session, as
well as resource materials for session discussions. The par-
ticipant manual provided the general format, outline, and
worksheets for each session. It included information
about diet and physical activity, and emphasized chang-
ing behaviors. This manual was intended to complement
the group session process and content by serving as a
workbook during the sessions and as a reference between
sessions.
The study also employed volunteer community health
advisors (CHAs) who were identified and recruited from
the same communities as the target population. These
"natural leaders" were trained to participate in all aspects
of the patient intervention. They assisted the intervention-
ists in conducting the group sessions and were asked to
lead portions of the activities or discussion so that the
intervention was delivered in conjunction with members
of the community. The CHAs also made monthly calls
during the 6 months while the intervention was delivered
and during the 12 months after the intervention. The pur-
Table 2: Baseline patient characteristics (N = 574)
Characteristic %*
N 574
Age, mean years (SD) 60.5 (11.4)
Female sex 61
Completed high school 93
Adequate income (self-reported) 85
African-American race 37
Medical history
Taking BP medications 95
Ever smoked 48
Physical activity (accelerometry), mean minutes/week (SD) 34 (106)
Diabetes 30
Hyperlipidemia 48
* Unless otherwise indicated.
BP = blood pressure; SD = standard deviation.Trials 2009, 10:13 http://www.trialsjournal.com/content/10/1/13
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pose of these calls was to provide one-on-one counseling
to encourage participants to make or maintain behavior
changes. The above-mentioned leader's guide was devel-
oped at the appropriate education level and with cultural
sensitivity so that it could also be used to train the CHAs.
The CHAs participated in a 20-hour training program con-
sisting of 4 weekly sessions covering general information
about hypertension, dietary and physical activity interven-
tions for BP control, community resources, facilitation of
group education sessions, practical guidelines for helping
peers, listening skills, lifestyle behavior change tech-
niques, and skills in stress management, problem-solving,
and goal setting. Certification and on-going supervision
were similar to that provided to the interventionists.
The CHAs served as familiar, non-authoritative resources
for study participants, strengthening communication
between the research group and the participants and pro-
viding additional social support. The intent is that the
CHAs will have sufficient knowledge and skills to serve as
ongoing resources in their communities and to help sus-
tain the effects of the project after it is completed.
The outcomes were measured at the level of the patient,
who was exposed to neither intervention, MD interven-
tion alone, patient intervention alone, or both interven-
tions. Overall, 8 practices (4 per treatment group), 32
physicians (4 per practice; 16 per treatment group), and
574 patients (289 control and 285 intervention) were
enrolled (Figure 2).
Physician measurements
Measurements specific to the physician intervention are
described above. All physicians, regardless of treatment
assignment, were asked to complete a baseline question-
naire concerning their demographics, education, and
training–variables that are potential mediators of the
effect of the physician intervention on BP control (Table
4). In addition, at entry, 6 months, and 18 months, all
physicians were asked to complete a questionnaire in
which they reported their practice patterns and habits. For
example, providers reported the average amount of time
spent discussing hypertension and lifestyle changes with
patients, in addition to addressing barriers to, confidence
in, and patient adherence to lifestyle modification coun-
seling.
Patient measurements
All study measurements obtained from participants were
collected during face-to-face clinic visits by trained, certi-
fied study personnel who were blinded to intervention
assignment. At each time point (baseline, 6- and 18-
month follow-up), BP was measured according to JNC-7
guidelines (i.e., seated quietly with back supported and
feet on the floor for 5 minutes prior, appropriate size cuff,
arm bared and supported, no ingestion or smoking for 30
minutes prior) by an oscillometric blood pressure
machine. At each study visit, average BP was defined as the
averaging of duplicate measurements taken on each of 2
separate visits at least 1 week apart. BP control was
defined based on JNC-7 guidelines: average systolic BP <
140 mm Hg and diastolic BP < 90 mm Hg for participants
without renal disease or diabetes, and systolic BP < 130
mm Hg and diastolic BP < 80 mm Hg for participants with
1 or both of these conditions. Other measurements
included weight/BMI, a dietary assessment using the
Block Food Frequency Questionnaire [27], a blood sam-
ple obtained after an overnight fast, a 24-hour urine col-
lection, an objective assessment of physical activity using
a triaxial accelerometer [28], an assessment of medication
Table 3: Behavioral change strategies of the HIP active intervention
Strategy Definition
Frequent contact Attend weekly sessions for 20 weeks.
Group interaction and social support Sessions were highly interactive and minimally didactic; participants were encouraged to share 
experiences that led to patient modeling behavior; they also were encouraged to help each other 
solve problems.
Goal setting and self-monitoring Emphasis placed on individual's ability to regulate his/her behavior by setting goals and monitoring 
progress towards the goals. Participants kept records of dietary intake, physical activity, and 
medication usage at least 3 days a week. Records were reviewed by the interventionist to provide 
feedback and encourage or support participant's behavior change.
Identification of barriers and problem-solving Interventions were patient-centered; interventionist assisted participant in identifying his/her own 
barriers and generating solutions.
Motivational interviewing Patient-centered counseling emphasized support of self-efficacy and optimism for change; included 
reflective listening, objective feedback, and respect.
HIP = Hypertension Improvement Project.Trials 2009, 10:13 http://www.trialsjournal.com/content/10/1/13
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adherence by self report, and psychosocial questionnaires.
The measurement schedules for patients and physicians
are shown in Table 5.
Primary and secondary outcomes
The primary outcome was the change in systolic BP at 6
months. Secondary outcomes included change in diasto-
lic BP, the proportion of participants with adequate BP
control at 6 and 18 months, and the effect of treatment on
behavior change (i.e., weight loss, dietary pattern, physi-
cal activity) at 6 and 18 months. The 6-month outcomes
correspond to the maximum impact of the patient inter-
vention but may be too early to reflect maximum impact
of the MD intervention. The 18-month outcomes assess
the durability of the patient intervention and the cumula-
tive (perhaps maximal) effect of the MD intervention.
Analysis plan
The data cleaning and analysis stage of the HIP trial has
begun. The adequacy of randomization will be assessed
by comparing the baseline characteristics of the 4 study
groups. Chi-square tests will be used for categorical varia-
bles, and the analysis of variance will be used for contin-
uous variables.
For the patient intervention groups only, various meas-
ures pertaining to adherence to the patient intervention
and its impact on intermediate outcomes will be summa-
rized. For example, for each cohort, the number of inter-
vention sessions attended will be summarized. Similarly,
changes in weight, diet, and exercise will be tabulated, and
whether the mean changes equal zero will be determined.
For the main analysis of BP changes, results by group and
cohort will first be summarized, and then tested for a
cohort-by-group interaction. If this interaction is non-sig-
nificant–suggesting that the intervention effects are simi-
lar across cohorts–summary results will be reported but
will include cohort as a control variable in all models. For
the continuous outcome of systolic BP, the main compar-
ison will be derived from an analysis of covariance model
that controls for cohort and baseline systolic BP. The pri-
mary hypotheses of interest will be the main effect of the
patient intervention, the main effect of the physician
intervention, and the patient-by-physician interaction.
This last interaction assesses, for example, whether the
patient and physician interventions have a separate
impact on outcome or, alternatively, whether they act syn-
ergistically. For the categorical outcome of percentage of
patients at goal, a similar strategy will be followed using
logistic regression, and these analyses will also be strati-
fied by whether the patient was at goal at baseline.
The analysis plan accounts for the correlations among the
responses for individual patients, these correlations being
induced by the nesting of time points within patients
within physicians within practices. The analysis of vari-
ance paradigm will be used, accounting for the correla-
tions among the 3 time points by separately analyzing the
paired scores representing differences between baseline
and 6 months and between baseline and 18 months.
These comparisons can be preceded by a statistical test,
such as Hotelling's T2, that takes explicit account of these
correlations.
Sample size and statistical power
The power calculations assumed that the impact of
accounting for covariates such as baseline blood pressure
(which increases statistical power) and the impact of the
clustering inherent to this design (which decreases statis-
tical power) would approximately offset and, thus, that
power calculations from the 1-way analysis of variance
would apply. If so, having approximately 340 patients
complete the study would yield approximately 80%
power to detect main effects, although the power to detect
an interaction between the physician intervention and
patient intervention would be smaller. After accounting
for expected drop-outs, the minimum sample size for the
primary analysis was set at 400.
Preliminary planning also considered 2 other factors,
both of which supported an increase in the sample size
above 400, if feasible. First, it was anticipated that the
study would analyze various secondary outcome varia-
bles, some of which might have effect sizes that were less
than 0.3. Second, so that the results could be as generaliz-
able as possible, the study strove to include as many clin-
ics as possible. The design originally intended to include
Table 4: Baseline physician characteristics (N = 32)
Characteristic %*
Age, mean years (SD) 47.9 (9.9)
Female sex 34
African-American race 16
Family medicine specialty 53
Internal medicine specialty 47
Years since MD degree, mean (SD) 20.7 (10.0)
Patients with HTN 28.9
Very familiar with JNC guidelines 31
* Unless otherwise indicated.
HTN = hypertension; JNC = Joint National Committee on 
Prevention, Evaluation, Detection, and Treatment of High Blood 
Pressure; SD = standard deviation.Trials 2009, 10:13 http://www.trialsjournal.com/content/10/1/13
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5 sets of clinics, a number which was also suggested by the
fact that the most conservative statistical analysis of the
impact of the physician intervention–namely, a sign test
that simply counts which clinic out of each pair had the
better outcome–would be statistically significant if the
physician intervention outperformed the controls at each
pair of clinics.
Near the conclusion of the 6-month follow-up for Cohort
3, the Data Safety Monitoring Board (DSMB) reviewed the
study design–in particular, whether it would, in view of
the trial's limited budget, be appropriate to reduce the
number of cohorts from 5 to 4. This DSMB review
included a comparison of the results of the study to date
(to which the investigators, with the exception of the
study statistician, were blinded) with the assumptions of
the power calculations. In approximate numbers, instead
of 40% of patients maintaining BP control at baseline, the
figure was actually 70%. Moreover, over 95% of the
patients who were in BP control at baseline were also in
control at 6 months, raising the possibility that using a
dichotomous BP control variable as the primary outcome
would suffer from a ceiling effect. (Note that such a ceiling
effect was not necessarily certain; for example, an effect
size of 0.3 could still be generated from a pattern of out-
comes centered around 70%, but this preliminary analysis
did suggest that patients who were in BP control at base-
line were likely to provide less information than desired
toward distinguishing the impacts of the interventions.)
In light of these considerations, the DSMB recommended:
(a) to reduce the number of cohorts to 4 (to conserve
budget); (b) to focus recruitment in Cohort 4 on patients
who were not in BP control at baseline (to ensure that the
study population approximated the original target popu-
lation as much as possible); and (c) to change the primary
Table 5: Measurement schedule
Time/variable Baseline 3 mo. 6 mo. 9 mo. 12 mo. 15 mo. 18 mo.
Physicians
Personal characteristics and training X
Practice habits (self-report) Xx x
Clinical performance measure (intervention group only) X xxx x x x
Participants
Blood pressure 
(Omron HEM-907, average of 4 readings at 2 visits 1 week apart)
Xx x
Weight Xx x
Fasting lipid panel Xx x
24-Hour urine collection Xx x
Diet (Block food frequency questionnaire) Xx x
Physical activity (7-day physical activity recall) Xx x
Physical activity (triaxial accelerometer) Xx x
Medication adherence (self-reported medication-taking scale) Xx x
Psychosocial mediators (SF-36, social support, perceived stress, depression) Xx x
Symptom questionnaire Xx x
Medication questionnaire Xx x
Process measures 
(patient intervention only: attendance, self-monitoring records)
Xx xTrials 2009, 10:13 http://www.trialsjournal.com/content/10/1/13
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outcome to change in SBP, measured as a continuous var-
iable, while maintaining the dichotomous measure of BP
control as a secondary outcome (to increase statistical
power by, for example, being able to differentiate between
greater decreases in SBP among patients who were in BP
control at baseline).
Cost analysis
The benefits of the proposed interventions must be
weighed in the context of the extent to which they can be
delivered systematically to large populations. Thus, the
logistical barriers and the actual costs of implementation
must be determined as part of an assessment of the value
of the HIP interventions. Ultimately, the implementation
costs of the patient and physician interventions can be
compared with each other and with other approaches to
improving BP control. Therefore, a cost analysis will be
performed to assess the direct costs of implementation,
accounting for both fixed and variable costs for start-up
and maintenance.
Discussion
The chronic care model suggests that BP control can be
achieved by improving patient self-care and the systems
through which care is delivered [29-32]. Patient self-care
efforts should be directed at counteracting the effects on
BP of obesity, physical inactivity, poor dietary pattern,
and non-adherence to prescribed medications [33]. Fur-
thermore, efforts should be made to promote the use of
quality improvement systems that can increase physician
adherence to established clinical practice guidelines
[34,35]. In addition to improving BP control, these
approaches can also reduce costs associated with hyper-
tension and its consequences [29]. However, given the
resources required to implement such approaches, it is
critical that their effectiveness be rigorously established
[36].
The Hypertension Improvement Project is a controlled
trial to test the separate and combined effects on BP of a
behavioral intervention for patients and a quality
improvement intervention for physicians. The patient
intervention employed proven behavioral methods for
promoting healthy lifestyle and adherence to medication
regimens. The physician intervention used a quality
improvement approach to provide training, motivation,
and feedback on performance in a non-threatening way to
promote continuous self-improvement and adherence to
clinical practice guidelines.
The physician intervention represents a form of quality
improvement that can be described as "Facilitated Process
Improvement" (FPI) [37]. Similar to CQI, FPI recognizes
that a key barrier to implementing systematic improve-
ment programs is provider time: time to become expert in
and to apply CQI methodology and time to become
familiar with the sorts of interventions that are likely to be
effective in a given context. In FPI, several components of
the CQI process are delegated to an expert team, with con-
current agreement by providers during education pro-
grams. In this case, the team identified the common
limiting barriers to optimal outcomes–lack of easy access
to guidelines and lack of ongoing feedback regarding con-
formance to guidelines (the latter issue may be termed
"the difficulty of looking over one's own shoulder")–and
created tools to address those barriers.
At the time at which this manuscript was prepared, the
trial was in progress. All physicians and patients had been
enrolled, and experience with the logistical aspects of
study conduct had been garnered. There are numerous
unique features and lessons gleaned thus far from the con-
duct of the trial that will set the stage for interpretation of
the study results. More importantly, these features and les-
sons can inform other investigators planning similar stud-
ies.
Several of the challenges faced relate to the setting in
which the trial is being conducted (Table 6). The study
team considered it important to conduct the study in
community clinics where such an approach to BP control
would ultimately be implemented. Implementation of
the HIP trial within a practice-based research network,
while innovative, also required attention to issues that are
not usually encountered within an academic medical
center (AMC). The study required access to work space
that was convenient and familiar to participants (i.e., in or
near the clinic) but that had minimal impact on clinical
care delivery. Not all medical clinics have space for study
visits and group intervention sessions. The study team
worked closely with clinic staff to schedule study visits on
days when clinic rooms were available (e.g., provider day
off) and used the waiting room (in the evenings), the
clinic conference room, or a nearby facility for the group
sessions.
Even though the study strived to cause minimal disrup-
tion to the usual clinic flow, the study team relied on the
assistance of clinic personnel to arrange and facilitate sev-
eral study processes. For example, clinic staff directed par-
ticipants to the appropriate location for study visits,
provided phlebotomy services, distributed blank CPM
forms, and collected completed CPM forms. Each of these
activities added to the staff's usual responsibilities, but
several approaches helped to promote cooperation
among study personnel and clinic personnel. First, the
study goals and procedures were explained to clinic per-
sonnel prior to start-up of a new site. During enrollment
and follow-up, the study team maintained frequent and
open communication among study coordinators, investi-Trials 2009, 10:13 http://www.trialsjournal.com/content/10/1/13
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gators, and clinic management. Lastly, the study budget
included modest compensation to the practices and to the
enrolled physicians.
Travel from the AMC to the distant sites (ranging 10–40
miles) was not a trivial issue. The study team tried to travel
as a group to minimize costs, and travel expenses were
reimbursed. Rising fuel costs during the study affected the
budget significantly.
Other challenges related to the choice of study popula-
tion. The initial goal was to recruit low-income, ethnic
minority participants, who are well-represented in the
communities served by the participating clinic network.
The study also aimed to comprise a population that was
approximately 40% male, as men are often under-repre-
sented in lifestyle intervention studies. Because partici-
pants were recruited from the practices of enrolled MDs
rather than the local community, previously effective tar-
geted recruitment procedures could not be relied upon
[38]. However, recruitment was targeted through access to
the clinical database serving the participating practices, in
which race, insurance, and sex data were available. Enroll-
ment of low-income participants was encouraged by tar-
geting recruitment efforts at patients in the database with
no insurance, or with Medicaid or Medicare without sup-
plemental insurance. Patient enrollment demographics
were monitored periodically so that subsequent recruit-
ment mailings could be prioritized to ensure a balanced
study population. Midway through enrollment, the pro-
portion of men was significantly below goal; in response,
mailings and recruitment calls were directed preferentially
to men. Despite these efforts, Table 2 indicates that most
study participants were at least high school-educated and
reported adequate financial resources, and fewer than
40% were men.
The patient intervention required weekly attendance at
group sessions that lasted up to 2 hours. Several of the
clinics served rural areas requiring significant travel by the
participants. Some communities were not accustomed to
the research activities of AMCs and, thus, patients in those
areas may have been less inclined to join a research study
for reasons related to lack of trust or information. While
these factors mimic challenges to implementation of the
patient intervention in real-world settings, they created a
greater challenge for recruitment into a research study,
especially given that recruitment was based on blind mail-
ings. The initial recruitment letter asked potential partici-
pants to call the study team only if they were not
interested in participating (an opt-out strategy); if the
study team did not receive a response, then a follow-up
call was made to answer any questions and determine
interest in participating. However, the ratio of calls to
enrollees was low, so the recruitment letter was changed
to allow patients to also opt in. This option allowed par-
ticipants to self-select for inclusion, which may have
selected more motivated individuals but is still likely to
generalize to a real-world implementation of the study
intervention, which would ultimately require voluntary
participation.
Recruitment of CHAs was somewhat challenging. The ini-
tial goal in enlisting CHAs was to recruit people with "nat-
ural helper" personalities from the same communities as
the target patient population. To that end, flyers were
posted in participating clinics, and clinic staffs and com-
munity leaders were asked to suggest people from within
their communities. The response to this recruitment effort
was relatively modest. Although we were able to recruit an
adequate number of CHAs for the study with a minimal
budget, our selection pool was limited. Future studies
incorporating the CHA element may consider including a
budget for a greater advertisement effort and other strate-
gies to enhance recruitment.
Challenges involving the physicians were also encoun-
tered. A few providers left their participating clinical prac-
tices during the course of the 18-month intervention. In
this situation, the provider's patients who were enrolled in
HIP were referred to another participating provider within
the practice. Also, completion of CPM forms often com-
peted with busy and varying clinic schedules, the
demands of patient care, or an upcoming review by the
Joint Commission on the Accreditation of Healthcare
Organizations. To minimize the additional work needed
for collecting the CPM data, non-carbon copy paper was
used, so that the top portion was used for the clinic note
and the bottom portion was used for data entry. This was
a brief 1-page form–the top portion was designed so that
non-MD personnel (e.g., a triage nurse) could fill out the
vital signs and medical history, while the bottom portion
was filled out by the provider stating the medication
changes and counseling that occurred during the visit. The
physician strategy was developed by the study investiga-
tors who were not fully aware of all the QI initiatives
(ongoing or planned) within the practices. The CPM
form, while short and simple, was viewed by the practice
staff as an additional form of which to keep track, and
they had to modify their usual procedures 1 day a month
to collect these data. With the increased use of electronic
medical records, future studies should be able to integrate
the collection of information about medication changes
and counseling within routine charting, although this
would also remove a reminder system that might contrib-
ute to improved BP management.
Developing the training modules was challenging due to
the availability of multiple hypertension guidelines [8,39-
41]. The original proposal was written when JNC-6 guide-Trials 2009, 10:13 http://www.trialsjournal.com/content/10/1/13
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Table 6: Study implementation issues
Challenge Solution
Setting
Access to clinic space for study visits Schedule study visits on days when clinic rooms are available.
Access to space for group intervention Schedule evening sessions; find local facility.
Minimize disruption to practice flow Study staff responsible for scheduling, check-in, and posting of signage.
Engage clinic staff/communication Group meeting prior to (and early part) of implementation; use of e-
mail; financial compensation to offset practice costs.
Travel to distant sites Staff coordinate travel together to minimize travel costs.
Patient population/recruitment
Enroll low SES population Target participants with no insurance, with Medicaid or Medicare 
without supplemental insurance.
Identify minority population Target clinics with more minority participants.
Recruit men to participate Prioritize mailings and phone calls to men.
High proportion of participants at BP goal 
(clinics are doing well in BP management; volunteer bias)
Chart review to identify patients with uncontrolled BP prior to 
screening for Cohort 4.
Group intervention
Finding patients motivated to undergo group intervention Recruitment by opt-out changed to opt-in/opt-out method.
Attendance Useful information; mimics real-world implementation.
No individualized counseling (allows implementation in busy setting) Use community health advisors.
Physician intervention
MD turnover Refer participants to another participating provider within practice.
Additional work for CPM form completion Form on non-carbon paper to use as clinic note; brief 1-page form; top 
part can be filled out by non-MD.
MD time for training module completion Face-to-face orientation of providers to Web-based (asynchronous) 
training modules; CME credits offered.
QI developed by researchers (non-practice staff); competing QI 
initiatives within practice
In future, increase involvement of practice clinicians; use of electronic 
records to collect BP at routine visits.
Town-gown relationship Work with existing research partner (PCRC).
BP = blood pressure; CME = continuing medical education; CPM = clinical performance measure; QI = Quality Improvement; JNC = Joint National 
Committee on Prevention, Evaluation, Detection, and Treatment of High Blood Pressure; MD = physician; PCRC = Primary Care Research 
Consortium; SES = socioeconomic status.Trials 2009, 10:13 http://www.trialsjournal.com/content/10/1/13
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lines were widely used; after the proposal was written and
before it was funded, the JNC-7 guidelines were released.
The training materials were modified to match the newer
version. To promote completion of the modules, they
were offered on the internet (allowing providers to com-
plete them when time was available), and providers were
given CME credit to provide additional incentive for the
time spent.
Overall, implementation of the study within a commu-
nity setting was facilitated by including the network direc-
tor (RJD) as part of the study team. The director had
worked with the practices and providers on previous stud-
ies, and so her pre-existing relationships aided recruit-
ment and troubleshooting of operational issues. Finally, it
is important to define rewards and compensation for
community practices, not only in terms of financial reim-
bursement, but also in terms of CME opportunities (cate-
gories 1 and 2), acknowledgment in publications, and
dissemination of study results.
Conclusion
Hypertension affects approximately 29% of the adult U.S.
population and remains a leading cause of heart disease,
stroke, and kidney failure. Despite numerous effective
treatments, only 53% of people with treated hypertension
are at goal blood pressure. The HIP interventions offered
an opportunity to significantly improve BP control and
lower CVD risk in a broad cross-section of hypertensive
patients from community primary care practices. The
study design will allow an assessment of the effectiveness
and cost of the physician and patient interventions sepa-
rately, so that health care organizations may make
informed decisions about implementation of 1 or both
interventions in the context of local resources.
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